Jun N-terminal Kinases (JNK) have been numerously implicated in models of neurodegenerative disease, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). JNK has also been shown to contribute to disease progression in models of fibrosis, such as Idiopathic Pulmonary Fibrosis (IPF) and Non-alcoholic Steatohepatitis (NASH). Because of JNK’s central role in multiple disease indications, many pharmaceutical companies have attempted to generate JNK selective, DMPK favorable and safe compounds, without success. At Imago Pharmaceuticals, we have overcome these hurdles with Development Candidate, IGP002, and now stand poised to advance into pre-IND development and clinical trials with this potential ground-breaking drug.
JNK DEVELOPMENT CANDIDATE: IGP002